{"entity":{"id":"christopher-flowers","kind":"person","name":"Christopher R. Flowers","aka":[],"tldr":"Christopher Flowers is a lymphoma specialist who leads MD Anderson's entire medical oncology division.","summary":"Christopher Flowers is Division Head of Cancer Medicine and Chair of Lymphoma and Myeloma at MD Anderson Cancer Center. A haematologist-oncologist, he focuses on lymphoma epidemiology, outcomes and disparities, and on trials of novel agents in diffuse large B-cell lymphoma and follicular lymphoma. His papers include a Journal of Clinical Oncology report on polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma and a review in CA: a Cancer Journal for Clinicians on improving outcomes for patients with the disease. He heads the Division of Cancer Medicine, the largest medical oncology group in the world, with work on CD20 and CD19 directed therapy.","asOf":"2026-09-08","links":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Christopher%20R.%20Flowers"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Flowers%20CR%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Christopher%20R.%20Flowers"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":["cd20","cd19"],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["ca-cancer-journal"],"dependsOn":[],"notes":[],"role":"Division Head, Cancer Medicine; Chair, Lymphoma and Myeloma, MD Anderson","institutionId":"md-anderson","specialisms":["Lymphoma","Health outcomes","Clinical trials"],"profiles":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Christopher%20R.%20Flowers"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Flowers%20CR%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Christopher%20R.%20Flowers"}],"papers":[{"title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","journal":"Journal of Clinical Oncology","year":2020,"url":"https://doi.org/10.1200/JCO.19.00172","doi":"10.1200/JCO.19.00172"},{"title":"Improving outcomes for patients with diffuse large B-cell lymphoma","journal":"CA: a Cancer Journal for Clinicians","year":2010,"url":"https://doi.org/10.3322/caac.20087","doi":"10.3322/caac.20087"}],"orcid":"0000-0002-9524-3990"},"route":"/people/christopher-flowers/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"}],"journal":[{"id":"ca-cancer-journal","kind":"journal","name":"CA: A Cancer Journal for Clinicians","route":"/journals/ca-cancer-journal/"}]}}